Published in The BMJ · View the paper (DOI)
Researchers argue that international drug development processes and policies are responsible for the lack of evidence supporting added benefits for most new drugs. Only 54 out of 216 assessed drugs showed considerable or major added benefits, with many more lacking clear evidence of benefit over standard care.
Coverage from 2 institutions